Benitec Biopharma (BNTC) EBT (2019 - 2025)
Benitec Biopharma (BNTC) posted EBT of -$28.2 million for Q4 2025, up 99.84% sequentially from -$17.4 billion in Q3 2025, and up 99.73% YoY from -$14.1 million in Q4 2024.
Benitec Biopharma (BNTC) EBT (2019 - 2025) Analysis & Trends
Benitec Biopharma has reported EBT for 7 years, with the latest figure at -$28.2 million in Q4 2025.
- Quarterly EBT rose 99.73% year-over-year to -$28.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$29.6 billion (down 64.51% YoY) and the FY2025 annual result came in at -$7.8 billion, down 228.5% from the prior year.
- EBT improved to -$28.2 million in Q4 2025 per BNTC's latest filing, from -$17.4 billion in the prior quarter.
- Over five years, EBT peaked at -$3.6 million in Q1 2022 and troughed at -$17.4 billion in Q3 2025.
- A 5-year average of -$2.4 billion and a median of -$8.3 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT slumped 78152.51% in 2024, then surged 99.73% in 2025.
- Over 5 years, EBT stood at -$5.0 million in 2021, then fell by 27.07% to -$6.3 million in 2022, then tumbled by 187.36% to -$18.2 million in 2023, then sank by 57110.74% to -$10.4 billion in 2024, then soared by 99.73% to -$28.2 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$28.2 million, -$17.4 billion, and -$10.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Benitec Biopharma | 577.39 Mn | 388.49 Mn | - | -28.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -28.20 Mn |
| Sep 30, 2025 | -17.38 Bn |
| Jun 30, 2025 | -10.19 Mn |
| Mar 31, 2025 | -12.18 Bn |
| Dec 31, 2024 | -10.42 Bn |
| Sep 30, 2024 | -4.86 Bn |
| Jun 30, 2024 | -2.35 Bn |
| Mar 31, 2024 | -357.43 Mn |
| Dec 31, 2023 | -18.21 Mn |
| Sep 30, 2023 | -6.22 Mn |
| Jun 30, 2023 | -16.44 Mn |
| Mar 31, 2023 | -5.84 Mn |
| Dec 31, 2022 | -6.34 Mn |
| Sep 30, 2022 | -5.38 Mn |
| Jun 30, 2022 | -4.93 Mn |
| Mar 31, 2022 | -3.60 Mn |
| Dec 31, 2021 | -4.99 Mn |
| Sep 30, 2021 | -5.05 Mn |
| Jun 30, 2021 | -4.05 Mn |
| Mar 31, 2021 | -3.80 Mn |